By Charles Bankhead
Source Medpagetoday
SAN ANTONIO — Postmastectomy chest-wall irradiation (CWI) for intermediate-risk breast cancer had no impact on long-term survival, results of a large British study showed.
After a median follow-up of 9.6 years, irradiated patients had a 10-year overall survival (OS) of 81.4% versus 82% for those who had no CWI. CWI led to a “clinically insignificant” reduction in chest-wall recurrence from 2.5% to 1.1%, representing a total of 29 recurrences among more than 1,600 women.
The results indicate that most women with intermediate-risk breast cancer can safely avoid CWI following mastectomy, said Ian Kunkler, MB BChir, of the University of Edinburgh in Scotland, at the San Antonio Breast Cancer Symposiumopens in a new tab or window (SABCS).
“Chest-wall irradiation did not improve 10-year overall survival, and it results in a clinically insignificant reduction in chest-wall recurrence of less than 2%,” Kunkler said during a press briefing. “It has no impact on disease-free or metastasis-free survival [DFS/MFS], and we believe these findings are consistent with incremental changes and improvements in multidisciplinary care [for breast cancer] over the period of the trial.”
“Adjuvant, chest-wall irradiation should be omitted in most patients meeting the eligibility of the SUPREMO opens in a new tab or windowtrial,” he stated.
Read more https://www.medpagetoday.com/meetingcoverage/sabcs/113417